Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn’s Disease

被引：0
|
作者：
Andrew P. Yu
Scott Johnson
Si-Tien Wang
Pavel Atanasov
Jackson Tang
Eric Wu
Jingdong Chao
Parvez M. Mulani
机构：
[1] Analysis Group,
[2] Inc.,undefined
[3] Abbott Laboratories,undefined
来源：
PharmacoEconomics | 2009年 / 27卷
关键词：
Infliximab; Adalimumab; Probabilistic Sensitivity Analysis; Tumour Necrosis Factor Antagonist; Infliximab Maintenance Therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: To determine and compare the cost utilities of the tumour necrosis factor (TNF) antagonists adalimumab and infliximab as maintenance therapies for patients in the US with moderately to severely active Crohn’s disease.
引用
收藏
页码：609 / 621
页数：12
相关论文
共 50 条
  • [1] Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn's Disease
    Yu, Andrew P.
    Johnson, Scott
    Wang, Si-Tien
    Atanasov, Pavel
    Tang, Jackson
    Wu, Eric
    Chao, Jingdong
    Mulani, Parvez M.
    PHARMACOECONOMICS, 2009, 27 (07) : 609 - 621
  • [2] Growth Improvement with Adalimumab Treatment in Children with Moderately to Severely Active Crohn's Disease
    Walters, Thomas D.
    Faubion, William A.
    Griffiths, Anne M.
    Baldassano, Robert N.
    Escher, Johanna
    Ruemmele, Frank M.
    Hyams, Jeffrey S.
    Lazar, Andreas
    Eichner, Samantha
    Huang, Bidan
    Li, Yao
    Thakkar, Roopal B.
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (06) : 967 - 975
  • [3] COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH USTEKINUMAB AS TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE IN THE UNITED STATES
    Zouraq, Azzabi, I
    Wilson, M.
    Hather, G.
    Curtis, R.
    Luo, M.
    Khalid, J. M.
    Minda, K.
    VALUE IN HEALTH, 2017, 20 (05) : A183 - A183
  • [4] COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN'S DISEASE FOR TURKEY
    Arhan, M.
    Tezel, H. A.
    Toruner, M.
    Bilaloglu, B.
    Koral, S.
    Ozer, E.
    VALUE IN HEALTH, 2018, 21 : S145 - S145
  • [5] Dual Advanced Therapies and Novel Pharmacotherapies for Moderately to Severely Active Crohn's Disease
    Tse, Chung Sang
    Dulai, Parambir S.
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2022, 51 (02) : 283 - 298
  • [6] Sustained Remission with Adalimumab Therapy in Japanese Patients with Moderately to Severely Active Crohn's Disease
    Hibi, Toshifumi
    Watanabe, Mamoru
    Kumar, Ashish
    Camez, Anne
    Lomax, Kathleen
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S463 - S463
  • [7] COST UTILITY ANALYSIS OF VEDOLIZUMAB VERSUS CONVENTIONAL THERAPY FOR BIOLOGIC-NAIVE, MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE PATIENTS IN CHINA
    Sheng, Y.
    Chen, J.
    Ma, L.
    Xie, L.
    Zhao, W.
    Han, Y.
    VALUE IN HEALTH, 2020, 23 : S533 - S533
  • [8] Clinical Benefit of Adalimumab Dose Adjustment for Patients With Moderately to Severely Active Crohn's Disease in EXTEND
    Colombel, Jean-Frederic
    Rutgeerts, Paul
    Sandborn, William
    Wolf, Douglas
    Reinisch, Walter
    Van Assche, Gert
    Eichner, Samantha
    Zhou, Qian
    Petersson, Joel
    Robinson, Anne
    Thakkar, Roopal
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S474 - S474
  • [9] INFLIXIMAB VERSUS ADALIMUMAB IN THE TREATMENT OF PERIANAL CROHN'S DISEASE
    Maas, Laura A.
    Limketkai, Berkeley N.
    Lazarev, Mark
    Melia, Joanna
    Selaru, Florin M.
    Parian, Alyssa M.
    GASTROENTEROLOGY, 2022, 162 (07) : S817 - S817
  • [10] The Safety and Efficacy of Induction and Maintenance Therapy with Infliximab in Children with Severely Active Crohn's Disease
    Kierkus, Jaroslaw
    Dadalski, Maciej
    Ryzko, Jozef
    Socha, Piotr
    Oracz, Grzegorz
    Szczepanski, Michal
    Szymanska, Edyta
    Socha, Jerzy
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S469 - S469
12345